Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00256399
Status:
COMPLETED
Last Update Posted:
2022-08-15
First Post:
2005-11-18
Brief Title:
Uroxatral in Men With Benign Prostate Hypertrophy BPH and Erectile Dysfunction ED
Sponsor:
University Hospitals Cleveland Medical Center
Organization:
University Hospitals Cleveland Medical Center
Study Overview
Official Title:
A Prospective Open Label Study to Assess the Efficacy of Alfuzosin 10 mg Tablet Once a Day in Male Subjects Suffering From Benign Prostate Hypertrophy Associated Lower Urinary Tract Symptoms and Erectile Dysfunction
Status:
COMPLETED
Status Verified Date:
2005-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Uroxatral alfuzosin may not only help BPH symptoms but may also improve sexual function in males with BPH and ED
Detailed Description:
The study will consist of a 30 day screeningwashout phase at the end of which qualified subjects will be assigned to alfuzosin 10 mg tablets once a day Subjects will be treated for 90 days The total duration of the study will be 120 days
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None